On November 27, 2018, Welldoc presented the webinar A Revolution in Diabetes Care: The Role and Value of Digital Therapeutics. Our speaker, Anand K. Iyer, PhD, MBA, is Welldoc’s Chief Strategy Officer. Anand is a leading global expert on digital health. He’s also a founding member of the board of directors for the Digital Therapeutics Alliance (DTA). This Insights offers a recap of the webinar and the opportunity to view a complete recording of the webinar.
Dr. Iyer laid out in stark terms the burden of diabetes in the U.S. Estimates from the CDC show 14% of U.S. adults have diabetes with the vast majority (95%) diagnosed with type 2 diabetes. Additionally an estimated 84 million Americans have prediabetes with many likely to develop type 2 diabetes. An exponential rise in these numbers is predicted. This will continue to increase the human toll and economic impact of diabetes. The situation is similar, if not more dire, across the globe.
To meet this growing U.S. and global challenge we need solutions and we need them now! The solutions must go beyond pharmacologic and device innovation which has not, to date, greatly improved diabetes care and outcomes.
Successful innovations to lessen the human toll and bend the cost curve must be based on delivering the right data to the right person at the right place and right time with the construct that data, plus information and knowledge will result in positive actions and outcomes.
The revolutionary solution Dr. Iyer elaborates on throughout this webinar is Digital Therapeutics. He defines and differentiates the handful of Digital Therapeutics distinct from the myriad available apps. He then details key considerations to implement and operationalize Digital Therapeutics in an array of settings using as an example the FDA cleared class 2 digital therapeutic BlueStar, powered by Welldoc.
The webinar includes an in-depth discussion of how Digital Therapeutics can, and increasingly will, assist health care entities to achieve the quadruple aim: improve health outcomes, lower costs, better patient experience and improve physician satisfaction. Dr. Iyer concludes the webinar with details of the analysis that Welldoc conducted with IBM Watson Health, formerly Truven Health Analytics, to determine the economic ROI of BlueStar to improve diabetes care and bend the cost curve.
Watch the recorded webinar here.